Last updated on May 2019

Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation

Brief description of study

Efficacy and safety of LNP023 in IgAN patients

Detailed Study Description

The purpose of this Phase IIa/IIb dose ranging study is to generate human data in the intended patient population with IgAN to establish clinical proof-of-concept and to evaluate dose responses to support dose selection for subsequent clinical development of LNP023 for IgAN and potentially other indications

Clinical Study Identifier: NCT03373461

Find a site near you

Start Over

Novartis Investigative Site

Melbourne, Australia
  Connect »